Q4 FY2026 EarningsQ4 FY26 beat consensus on both top and bottom lines: revenue of $28.6M vs. $26.5M expected, and gross margin of 54.8% vs. 52.9% expected. Despite the revenue surge of 66% YoY, GAAP EPS of -$0.67 missed the -$0.60 consensus, primarily due to increased operating expenses from commercial expansion. FY27 revenue guidance of $137M was issued, implying a 44% YoY growth trajectory as the ASSURE® system gains market share.
Financial report interval: 2026.01.30 - 2026.04.30
Preview: Kestra Medical Tech(KMTS) predict that the Revenue is 28.64 M (+66.18%), Beat estimate;the EBIT is -39.34 M (+18.39%), Miss estimate;the EPS is -0.67 (+69.68%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.03B66.18%
0.03B53.66%
+0.00B12.52%
EBITMiss expectations
-0.04B18.39%
-0.03B29.15%
-0.01B10.76%
EPSMiss expectations
-0.6769.68%
-0.595773.04%
-0.07433.36%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf